Flame Biosciences to Ignite Pipeline with $100M Common Stock Financing

Flame Biosciences is ready to take their potentially best-in-class therapy for the treatment of lung cancers driven by inflammation into the next phase thanks to an infusion of cash from a common stock financing. A hefty $100 million was raised this week in an effort led by Rock Springs Capital.